TY - JOUR
T1 - Optical coherence tomography in multiple sclerosis
T2 - A systematic review and meta-analysis
AU - Petzold, Axel
AU - de Boer, Johannes F.
AU - Schippling, Sven
AU - Vermersch, Patrik
AU - Kardon, Randy
AU - Green, Ari
AU - Calabresi, Peter A.
AU - Polman, Chris
N1 - Funding Information:
We thank Philipp Albrecht, Luc Jeanjean, and Fiona Costello for providing details of their published data for the meta-analysis. JFdB has received research funding and funding for equipment from Foundation for Fundamental Research on Matter, Netherlands Organisation for Scientific Research, and US National Institutes of Health. RK has received research support from the National Eye Institute of the National Institutes of Health. AG receives research support from the National Institutes of Health and Howard Hughes Medical Institute. He has previously been funded by the National MS Society and American Academy of Neurology Foundation.
Funding Information:
AP has received consulting fees from Novartis. PV has received honoraria from Heidelberg Engineering. SS has received research grants from Biogen Idec and Bayer Schering Pharma and consulting fees from Bayer Schering Pharma, Merck Serono, and Sanofi-Aventis. AG has received payment for services from Biogen Idec and Applied Clinical Intelligence for work on a clinical endpoint adjudication committee related to clinical trials of daclizumab and from Projects in Knowledge for editorial work on CME-related publications. He has also received honoraria from Novartis Pharmaceuticals and PROCE CME. PAC has received grants from Biogen Idec, Teva, Vertex, Bayer, Genentech, and Serono and consulting fees from Novartis, Biogen Idec, Teva, Vertex, Novo Nordisk, Centacor, Serono, and Genentech. CP has received institutional grants from Novartis, Biogen Idec, Bayer Schering, GlaxoSmithKline, UCB, Merck Serono, and Teva, consultancy fees from Actelion, Biogen Idec, Bayer Schering, Teva, Merck Serono, Novartis, GlaxoSmithKline, UCB, Roche, Antisense Therapeutics, and has provided expert testimony for Biogen Idec. SS, PV, RK, AG, PAC, and CP sit on the Novartis steering committee for a multicentre observational study, and receive honoraria. JFdB has no conflicts of interest.
PY - 2010/9
Y1 - 2010/9
N2 - Optical coherence tomography (OCT) is a new method that could aid analysis of neurodegeneration in multiple sclerosis (MS) by capturing thinning of the retinal nerve fibre layer (RNFL). Meta-analyses of data for time domain OCT show RNFL thinning of 20·38 μm (95% CI 17·91-22·86, n=2063, p<0·0001) after optic neuritis in MS, and of 7·08 μm (5·52-8·65, n=3154, p<0·0001) in MS without optic neuritis. The estimated RNFL thinning in patients with MS is greater than the extent expected in normal ageing, probably because of retrograde trans-synaptic degeneration and progressive loss of retinal ganglion cells, in addition to the more pronounced thinning caused by optic neuritis if present. RNFL thickness correlates with visual and neurological functioning as well as with paraclinical data. Developments that could improve understanding of the relation between structure and function in MS pathophysiology include spectral or Fourier domain OCT technology, polarisation-sensitive OCT, fluorescence labelling, structural assessment of action-potential propagation, and segmentation algorithms allowing quantitative assessment of retinal layers.
AB - Optical coherence tomography (OCT) is a new method that could aid analysis of neurodegeneration in multiple sclerosis (MS) by capturing thinning of the retinal nerve fibre layer (RNFL). Meta-analyses of data for time domain OCT show RNFL thinning of 20·38 μm (95% CI 17·91-22·86, n=2063, p<0·0001) after optic neuritis in MS, and of 7·08 μm (5·52-8·65, n=3154, p<0·0001) in MS without optic neuritis. The estimated RNFL thinning in patients with MS is greater than the extent expected in normal ageing, probably because of retrograde trans-synaptic degeneration and progressive loss of retinal ganglion cells, in addition to the more pronounced thinning caused by optic neuritis if present. RNFL thickness correlates with visual and neurological functioning as well as with paraclinical data. Developments that could improve understanding of the relation between structure and function in MS pathophysiology include spectral or Fourier domain OCT technology, polarisation-sensitive OCT, fluorescence labelling, structural assessment of action-potential propagation, and segmentation algorithms allowing quantitative assessment of retinal layers.
UR - http://www.scopus.com/inward/record.url?scp=77955596271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955596271&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(10)70168-X
DO - 10.1016/S1474-4422(10)70168-X
M3 - Review article
C2 - 20723847
AN - SCOPUS:77955596271
VL - 9
SP - 921
EP - 932
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 9
ER -